The estimated Net Worth of Anthony Scott Praill is at least $63.5 Tausend dollars as of 5 October 2017. Anthony Praill owns over 17,500 units of DelMar Pharmaceuticals stock worth over $63,470 and over the last 11 years Anthony sold DMPI stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anthony Praill DMPI stock SEC Form 4 insiders trading
Anthony has made over 5 trades of the DelMar Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently Anthony bought 17,500 units of DMPI stock worth $14,875 on 5 October 2017.
The largest trade Anthony's ever made was buying 50,000 units of DelMar Pharmaceuticals stock on 16 July 2015 worth over $30,000. On average, Anthony trades about 3,377 units every 48 days since 2013. As of 5 October 2017 Anthony still owns at least 47,366 units of DelMar Pharmaceuticals stock.
You can see the complete history of Anthony Praill stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Anthony Praill's mailing address?
Anthony's mailing address filed with the SEC is 12707 HIGH BLUFF DR., SUITE 200, SAN DIEGO, CA, 92130.
Insiders trading at DelMar Pharmaceuticals
Over the last 11 years, insiders at DelMar Pharmaceuticals have traded over $104,000 worth of DelMar Pharmaceuticals stock and bought 663,835 units worth $651,854 . The most active insiders traders include John K Bell, Robert Hoffman und Jeffrey Bacha. On average, DelMar Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $20,766. The most recent stock trade was executed by John K Bell on 13 September 2019, trading 35,000 units of DMPI stock currently worth $23,800.
What does DelMar Pharmaceuticals do?
DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
What does DelMar Pharmaceuticals's logo look like?
Complete history of Anthony Praill stock trades at DelMar Pharmaceuticals
DelMar Pharmaceuticals executives and stock owners
DelMar Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Saiid Zarrabian,
President, Chief Executive Officer, Director -
Scott Praill,
Chief Financial Officer -
Dennis Brown,
Chief Scientific Officer -
Robert Hoffman,
Independent Chairman of the Board -
Robert Toth,
Independent Director -
Keith Murphy,
Director -
John Liatos,
Director -
Erich Mohr,
Director -
Napoleone Ferrara,
Director -
John K Bell,
Director -
Lynda Sarah Cranston,
Director -
William J Garner,
Director -
Jeffrey Bacha,
Chief Executive Officer